MTSL Issue 809

 Comments Off on MTSL Issue 809
Aug 232015
 
MTSL Issue 809

Issue No. 809 (dated 8/20/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ACAD #ANTH #NVAX #OGXI #ZIOP

Novavax Update (8-11-15)

 Comments Off on Novavax Update (8-11-15)
Aug 112015
 
Novavax Update (8-11-15)

Special Update – NVAX – Positive Phase II RSV Vaccine Data De-Risks The Crown Jewel – Raising Buy Limit and Target Price – In the large Phase II trial, NVAX has delivered excellent RSV F protein vaccine data in the most difficult-to-treat elderly population (>60 years old). The study is the first ever demonstration of efficacy of an active RSV vaccine in humans, read more…

MTSL Issue 808

 Comments Off on MTSL Issue 808
Aug 092015
 
MTSL Issue 808

Issue No. 808 (dated 8/6/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ALKS #ANTH #BMRN #INCY #ISIS #MDCO #NKTR #NVAX #PCRX #SGMO #ZIOP

MTSL Issue 807

 Comments Off on MTSL Issue 807
Jul 262015
 
MTSL Issue 807

Issue No. 807 (dated 7/23/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ANTH #BMRN #ISIS #MDCO #NKTR #NVAX

MoneyShow – Top Picks Mid-Year Winners: Jay Silverman (7-6-15)

 Comments Off on MoneyShow – Top Picks Mid-Year Winners: Jay Silverman (7-6-15)
Jul 062015
 
MoneyShow - Top Picks Mid-Year Winners: Jay Silverman (7-6-15)

In January, MoneyShow asked all of the nation’s leading advisors to select a favorite stock for 2015. In this special series of interviews we are talking with the five advisors who had the top performing stock picks as of mid-year. Here, we talk with Jay Silverman, editor of The Medical Technology Stock Letter, to discuss a top performing biotechnology company.

MoneyShow: Biotech Catalysts (6-22-15)

 Comments Off on MoneyShow: Biotech Catalysts (6-22-15)
Jun 302015
 
MoneyShow:  Biotech Catalysts (6-22-15)

Our guest today is Jay Silverman, a leading biotechnology sector analyst and editor of The Medical Technology Stock Letter. He updates us on the acquisition of one of his long-standing recommendations, the impact of this deal on the biotech space, and a trio of additional ideas for long-term investors to consider.

MTSL Issue 803

 Comments Off on MTSL Issue 803
May 152015
 
MTSL Issue 803

Issue No. 803 (dated 5/14/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ACAD, #ISIS, #MDCO, #NVAX, #SGMO and #ZIOP

MoneyShow: A Trio of Biotech Favorites (4-6-15)

 Comments Off on MoneyShow: A Trio of Biotech Favorites (4-6-15)
Apr 062015
 
MoneyShow: A Trio of Biotech Favorites (4-6-15)

Our guest today is Jay Silverman, a leading biotechnology sector analyst and editor of The Medical Technology Stock Letter. He updates us on the acquisition of one of his long-standing recommendations, the impact of this deal on the biotech space, and a trio of additional ideas for long-term investors to consider.

SENTIMENT – A CORE MTSL INVESTMENT METHODOLOGY

 Comments Off on SENTIMENT – A CORE MTSL INVESTMENT METHODOLOGY
Feb 262015
 
SENTIMENT - A CORE MTSL INVESTMENT METHODOLOGY

Sentiment – A Core MTSL Investment Methodology February 19, 2015 The most recent reading of the CNN/Money Fear and Greed Indicator has entered the “Extreme Greed” range. While very short-term in nature, it represents the level of expectations investors have in stocks and today that level is quite high. It all suggests that while stocks may […]

The Comparables

 Comments Off on The Comparables
Jan 122015
 
The Comparables

The Comparables    January 8, 2015 The Comparables– During the past year or so, biotech experienced an unprecedented number of companies going public. Over that period, we have added two such names to our portfolio – PCRX (2012) and FPRX (2014). A handful of these stocks have achieved remarkable valuations in a very short time […]

Biotech Fund Managers – What The Pros Do Every Year

 Comments Off on Biotech Fund Managers – What The Pros Do Every Year
Aug 222014
 
Biotech Fund Managers - What The Pros Do Every Year

Biotech Fund Managers – What The Pros Do Every Year  August 21, 2014   The Medical Technology Stock Letter (“MTSL”) prides itself on identifying exciting small companies that will become leaders in their respective fields over time. We emphasize “over time” because that is the nature of drug development and compounded returns of successful biotech […]

A BRIEF IMMUNE-ONCOLOGY UPDATE

 Comments Off on A BRIEF IMMUNE-ONCOLOGY UPDATE
Jun 202014
 
A BRIEF IMMUNE-ONCOLOGY UPDATE

A BRIEF IMMUNE-ONCOLOGY UPDATE June 12, 2014 ASCO 2014 – Immune Oncology Rises to the Top – As many expected, immune oncology (I-O) was all the rage at the recently concluded American Society of Clinical Oncology (ASCO) meeting.  While it is widely acknowledged that before ASCO, Bristol was the leader in the space followed by […]

NOT YOUR FATHER’S PLATFORMS

 Comments Off on NOT YOUR FATHER’S PLATFORMS
May 172014
 
NOT YOUR FATHER’S PLATFORMS

NOT YOUR FATHER’S PLATFORMS May 15, 2014 MTSL published Issue #753 “Plentiful Platforms” on April 25, 2012.  Most of our platform recommendations have made significant progress since then, and our subscriber base has grown substantially as well.  Many new customers may not have (understandably) had a chance to read our archives (although they all reside […]